News
Regeneron, playing catch-up with J&J and Pfizer, wins FDA approval for Lynozyfic in multiple myeloma
Another BCMA-targeted agent has arrived for the treatment of multiple myeloma. | After a delay, Regeneron’s BCMA-directed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback